SORAFENIB Side Effects

7022895-8 | Diarrhoea, Infection
on Sep 02, 2010 Female patient from GERMANY , 58 years of age, was diagnosed with hepatic neoplasm malignant, gastritis, hypotension and was treated with Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, infection (What is infection?). Sorafenib dosage: Unit Dose: 400 Mg. During the same period patient was treated with RANITIDINE HCL (View Ranitidine Hcl Review and Ranitidine Hcl Label ), EFFORTIL (View Effortil Review and Effortil Label ). Patient was hospitalized.

7022894-6 | Febrile Neutropenia
Patient was taking Sorafenib (View Usage). Patient had the following side effects: febrile neutropenia on Sep 23, 2010 from UNITED STATES Additional patient health information: Male patient , 54 years of age, weighting 207.2 lb, was diagnosed with thyroid cancer metastatic, depression (What is depression?), hypertension, diarrhoea, upper respiratory tract infection and. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with LEVOXYL (View Levoxyl Review and Levoxyl Label ), AMITRIPTYLINE HCL (View Amitriptyline Hcl Review and Amitriptyline Hcl Label ), NORVASC (View Norvasc Review and Norvasc Label ), IMODIUM (1 Tablet) (View Imodium Review and Imodium Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ). Patient was hospitalized.

7020843-8 | Hepatic Function Abnormal
Adverse event was reported on Sep 24, 2010 by a Male patient taking Sorafenib (View Usage) (Dosage: ) was diagnosed with hepatic neoplasm malignant, pain (What is pain?), hepatitis b (What is hepatitis b?), rash (What is rash?) and. Location: HONG KONG , 46 years of age, weighting 121.3 lb, After Sorafenib was administered, patient had the following side effects: hepatic function abnormal. During the same period patient was treated with DF 118 (View Df 118 Review and Df 118 Label ), LAMIVUDINE (View Lamivudine Review and Lamivudine Label ), ADEFOVIR DIPIVOXIL KIT (View Adefovir Dipivoxil Kit Review and Adefovir Dipivoxil Kit Label ), SYNALAR (View Synalar Review and Synalar Label ), VIOFORM (View Vioform Review and Vioform Label ).

7020840-2 | Abdominal Pain, Diabetes Mellitus, Dyspepsia, Fatigue, Liver Function Test Abnormal
on Sep 27, 2010 Male patient from AUSTRALIA , 72 years of age, weighting 180.8 lb, was diagnosed with hepatic neoplasm malignant, diabetes mellitus, gout (What is gout?), hypertension, gastrooesophageal reflux disease and was treated with Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), diabetes mellitus, dyspepsia, fatigue, liver function test abnormal. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), PROGOUT (Total Daily Dose: 300 Mg) (View Progout Review and Progout Label ), BETALOC (Total Daily Dose: 100 Mg) (View Betaloc Review and Betaloc Label ), ZESTRIL (View Zestril Review and Zestril Label ), LOVAZA (View Lovaza Review and Lovaza Label ), INSULIN NOVORAPID (View Insulin Novorapid Review and Insulin Novorapid Label ), SOMAC (View Somac Review and Somac Label ). Patient was hospitalized.


7020839-6 | Blood Bilirubin Increased, Diarrhoea, Encephalopathy
on Sep 23, 2010 Male patient from CANADA , 69 years of age, was diagnosed with hepatic neoplasm malignant and was treated with Sorafenib (View Usage). Patient had the following side effects: blood bilirubin increased, diarrhoea, encephalopathy. Sorafenib dosage: . During the same period patient was treated with ERLOTINIB HYDROCHLORIDE (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ), VALSARTAN (Total Daily Dose: 80 Mg Unit Dose: 80 Mg) (View Valsartan Review and Valsartan Label ), DIMENHYDRINATE (Unit Dose: 50 Mg) (View Dimenhydrinate Review and Dimenhydrinate Label ), LORAZEPAM (Total Daily Dose: 1 Mg Unit Dose: 1 Mg) (View Lorazepam Review and Lorazepam Label ), FUROSEMIDE (Total Daily Dose: 20 Mg Unit Dose: 20 Mg) (View Furosemide Review and Furosemide Label ), ACETAMINOPHEN (Unit Dose: 325 Mg) (View Acetaminophen Review and Acetaminophen Label ), NADOLOL (Total Daily Dose: 40 Mg Unit Dose: 80 Mg) (View Nadolol Review and Nadolol Label ), PANTOPRAZOLE (Total Daily Dose: 40 Mg Unit Dose: 40 Mg) (View Pantoprazole Review and Pantoprazole Label ). Patient was hospitalized.

7020806-2 | Anaemia, Dehydration, Gastrointestinal Haemorrhage, Gastrointestinal Ulcer
Patient was taking Sorafenib (View Usage). After Sorafenib was administered, patient had the following side effects: anaemia, dehydration, gastrointestinal haemorrhage, gastrointestinal ulcer on Sep 24, 2010 from UNITED STATES Additional patient health information: Female patient , 81 years of age, weighting 130.1 lb, was diagnosed with breast cancer metastatic, type 2 diabetes mellitus, hypertension and. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with TAXOL (Total Daily Dose: 126 Mg Unit Dose: 90 Mg/m2) (View Taxol Review and Taxol Label ), GLUCOPHAGE (Total Daily Dose: 1500 Mg Unit Dose: 1500 Mg) (View Glucophage Review and Glucophage Label ), DIABETA (Total Daily Dose: 5 Mg Unit Dose: 5 Mg) (View Diabeta Review and Diabeta Label ), ACTOS (Total Daily Dose: 30 Mg Unit Dose: 30 Mg) (View Actos Review and Actos Label ), NORVASC (Total Daily Dose: 5 Mg Unit Dose: 5 Mg) (View Norvasc Review and Norvasc Label ), ACCUPRIL (Total Daily Dose: 5 Mg Unit Dose: 5 Mg) (View Accupril Review and Accupril Label ). Patient was hospitalized.

7020805-0 | Hepatic Function Abnormal, Meningitis
Adverse event was reported on Sep 24, 2010 by a Female patient taking Sorafenib (View Usage) (Dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg) was diagnosed with breast cancer metastatic and. Location: UNITED STATES , 39 years of age, weighting 141.1 lb, Patient experienced the following unwanted or unexpected effects: hepatic function abnormal, meningitis (What is meningitis?). During the same period patient was treated with TAXOL (Unit Dose: 90 Mg/m2) (View Taxol Review and Taxol Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ). Patient was hospitalized.

7020274-0 | Ascites, Blood Creatinine Abnormal, Dyspnoea, Hyperkalaemia, Hyponatraemia, Lethargy
on Sep 21, 2010 Male patient from SINGAPORE , 61 years of age, weighting 127.9 lb, was diagnosed with hepatic neoplasm malignant, abdominal discomfort, blood albumin decreased, hepatitis (What is hepatitis?), hepatic vein thrombosis and was treated with Sorafenib (View Usage). Patient had the following side effects: ascites, blood creatinine abnormal, dyspnoea, hyperkalaemia, hyponatraemia, lethargy. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), 20% ALBUMIN (View 20% Albumin Review and 20% Albumin Label ), LAMIVUDINE (View Lamivudine Review and Lamivudine Label ), CLEXANE (View Clexane Review and Clexane Label ). Patient was hospitalized.

7020066-2 | Acute Coronary Syndrome, Acute Prerenal Failure, Anaemia, Cardiac Failure Congestive, Confusional State, Dehydration, Diverticulum, Gastrointestinal Haemorrhage, Gastrointestinal Ulcer
on Sep 24, 2010 Female patient from UNITED STATES , 81 years of age, weighting 119.0 lb, was diagnosed with breast cancer metastatic, type 2 diabetes mellitus, hypertension and was treated with Sorafenib (View Usage). After Sorafenib was administered, patient had the following side effects: acute coronary syndrome, acute prerenal failure, anaemia, cardiac failure congestive, confusional state, dehydration, diverticulum, gastrointestinal haemorrhage, gastrointestinal ulcer. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with TAXOL (Total Daily Dose: 126 Mg Unit Dose: 90 Mg/m2) (View Taxol Review and Taxol Label ), GLUCOPHAGE (Total Daily Dose: 1500 Mg Unit Dose: 1500 Mg) (View Glucophage Review and Glucophage Label ), DIABETA (Total Daily Dose: 5 Mg Unit Dose: 5 Mg) (View Diabeta Review and Diabeta Label ), ACTOS (Total Daily Dose: 30 Mg Unit Dose: 30 Mg) (View Actos Review and Actos Label ), NORVASC (Total Daily Dose: 5 Mg Unit Dose: 5 Mg) (View Norvasc Review and Norvasc Label ), ACCUPRIL (Total Daily Dose: 5 Mg Unit Dose: 5 Mg) (View Accupril Review and Accupril Label ). Patient was hospitalized.

7020064-9 | Hepatic Function Abnormal, Meningitis
Patient was taking Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic function abnormal, meningitis (What is meningitis?) on Sep 24, 2010 from UNITED STATES Additional patient health information: Female patient , 39 years of age, weighting 141.1 lb, was diagnosed with breast cancer metastatic and. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with TAXOL (Unit Dose: 90 Mg/m2) (View Taxol Review and Taxol Label ), WARFARIN (View Warfarin Review and Warfarin Label ). Patient was hospitalized.

7020045-5 | Back Pain, Lung Infiltration, Respiratory Failure
Adverse event was reported on Sep 23, 2010 by a Female patient taking Sorafenib (View Usage) (Dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg) was diagnosed with pancreatic carcinoma and. Location: UNITED STATES , 58 years of age, weighting 180.8 lb, Patient had the following side effects: back pain (What is back pain?), lung infiltration, respiratory failure. During the same period patient was treated with ERLOTINIB HYDROCHLORIDE (Total Daily Dose: 150 Mg) (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ). Patient was hospitalized.

7014817-0 | Basal Ganglia Infarction, Breast Cancer, Clostridial Infection, Dehydration, Urosepsis
on Sep 17, 2010 Female patient from UNITED STATES , 79 years of age, weighting 134.5 lb, was diagnosed with malignant melanoma, hypertension, hypercholesterolaemia and was treated with Sorafenib (View Usage). After Sorafenib was administered, patient had the following side effects: basal ganglia infarction, breast cancer (What is breast cancer?), clostridial infection, dehydration, urosepsis. Sorafenib dosage: As Used: 200-400 Mg Unit Dose: 200 Mg. During the same period patient was treated with AMIODARONE HCL (View Amiodarone Hcl Review and Amiodarone Hcl Label ), DILTIAZEM (Total Daily Dose: 90 Mg Unit Dose: 30 Mg) (View Diltiazem Review and Diltiazem Label ), GABAPENTIN (Total Daily Dose: 600 Mg) (View Gabapentin Review and Gabapentin Label ), LIPITOR (Total Daily Dose: 10 Mg Unit Dose: 20 Mg) (View Lipitor Review and Lipitor Label ), LOPERAMIDE (View Loperamide Review and Loperamide Label ). Patient was hospitalized.

7014815-7 | Hyponatraemia, Skin Ulcer
on Sep 23, 2010 Male patient from TAIWAN, PROVINCE OF CHINA , 56 years of age, weighting 176.4 lb, was diagnosed with hepatic neoplasm malignant and was treated with Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: hyponatraemia, skin ulcer. Sorafenib dosage: Total Daily Dose: 400 Mg. During the same period patient was treated with MOSAPRIDE CITRATE (Total Daily Dose: 15 Mg) (View Mosapride Citrate Review and Mosapride Citrate Label ), MELOXICAM (View Meloxicam Review and Meloxicam Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), SILYMARIN (Total Daily Dose: 450 Mg) (View Silymarin Review and Silymarin Label ), MEGESTROL (Total Daily Dose: 80 Mg) (View Megestrol Review and Megestrol Label ), DILTIAZEM (Long Acting) (View Diltiazem Review and Diltiazem Label ). Patient was hospitalized.

7014584-0 | Fatigue, Mucosal Inflammation, Palmar-plantar Erythrodysaesthesia Syndrome
Patient was taking Sorafenib (View Usage). Patient had the following side effects: fatigue, mucosal inflammation, palmar-plantar erythrodysaesthesia syndrome on Aug 25, 2010 from UNITED STATES Additional patient health information: Male patient , 54 years of age, was diagnosed with hepatic neoplasm malignant recurrent and. Sorafenib dosage: Total Daily Dose: 400 Mg. During the same period patient was treated with SIROLIMUS (View Sirolimus Review and Sirolimus Label ).

7013292-X | Cerebral Ischaemia, Deep Vein Thrombosis
Adverse event was reported on Sep 23, 2010 by a Male patient taking Sorafenib (View Usage) (Dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg) was diagnosed with non-small cell lung cancer, diabetes mellitus, coronary artery disease (What is coronary artery disease?), hypertension, prophylaxis, hyperlipidaemia and. Location: GREECE , 68 years of age, weighting 172.0 lb, After Sorafenib was administered, patient had the following side effects: cerebral ischaemia, deep vein thrombosis (What is deep vein thrombosis?). During the same period patient was treated with SOLOSA (View Solosa Review and Solosa Label ), GLUCOPHAGE (View Glucophage Review and Glucophage Label ), EUCREAS (View Eucreas Review and Eucreas Label ), ISCOVER (View Iscover Review and Iscover Label ), CARVEDILOL (View Carvedilol Review and Carvedilol Label ), TRIATEC (View Triatec Review and Triatec Label ), LIPITOR (View Lipitor Review and Lipitor Label ). Patient was hospitalized and became disabled.

7013264-5 | Hepatic Encephalopathy, Hepatic Failure, Jaundice, Renal Failure
on Sep 15, 2010 Male patient from UNITED KINGDOM , 63 years of age, weighting 154.3 lb, was diagnosed with renal cell carcinoma, hypertension, dyspepsia and was treated with Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic encephalopathy, hepatic failure, jaundice (What is jaundice?), renal failure. Sorafenib dosage: Total Daily Dose: 800 Mg. During the same period patient was treated with BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), FELODIPINE (View Felodipine Review and Felodipine Label ), ACETAMINOPHEN (Unit Dose: 500 Mg) (View Acetaminophen Review and Acetaminophen Label ), CEFTRIAXONE (Unit Dose: 2 G) (View Ceftriaxone Review and Ceftriaxone Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), ACETYLCYSTEINE (Over 15 Mins) (View Acetylcysteine Review and Acetylcysteine Label ). Patient was hospitalized.

7012030-4 | Hypotension, Loss Of Consciousness, Rash
on Sep 21, 2010 Male patient from RUSSIAN FEDERATION , 64 years of age, weighting 158.7 lb, was diagnosed with hepatic neoplasm malignant, hypertension and was treated with Sorafenib (View Usage). Patient had the following side effects: hypotension, loss of consciousness, rash (What is rash?). Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with BETALOC (View Betaloc Review and Betaloc Label ), PREDUCTAL (View Preductal Review and Preductal Label ), MONOPRIL (View Monopril Review and Monopril Label ). Patient was hospitalized.

7012028-6 | Hepatic Encephalopathy, Hepatic Failure, Jaundice, Renal Failure
Patient was taking Sorafenib (View Usage). After Sorafenib was administered, patient had the following side effects: hepatic encephalopathy, hepatic failure, jaundice (What is jaundice?), renal failure on Sep 15, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 63 years of age, weighting 154.3 lb, was diagnosed with renal cell carcinoma, hypertension, dyspepsia and. Sorafenib dosage: Total Daily Dose: 800 Mg. During the same period patient was treated with BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), FELODIPINE (View Felodipine Review and Felodipine Label ), ACETAMINOPHEN (Unit Dose: 500 Mg) (View Acetaminophen Review and Acetaminophen Label ), CEFTRIAXONE (Unit Dose: 2 G) (View Ceftriaxone Review and Ceftriaxone Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), ACETYLCYSTEINE (Over 15 Mins) (View Acetylcysteine Review and Acetylcysteine Label ). Patient was hospitalized.

7009861-3 | Anaemia, Aphasia, Diarrhoea, Dyspnoea, Fatigue, Hypokalaemia, Tachycardia
Adverse event was reported on Sep 14, 2010 by a Female patient taking Sorafenib (View Usage) (Dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg) was diagnosed with colorectal cancer metastatic, pulmonary congestion, diarrhoea, mineral supplementation and. Location: UNITED STATES , 65 years of age, weighting 134.5 lb, Patient experienced the following unwanted or unexpected effects: anaemia, aphasia (What is aphasia?), diarrhoea, dyspnoea, fatigue, hypokalaemia, tachycardia. During the same period patient was treated with RDEA119 (Total Daily Dose: 100 Mg) (View Rdea119 Review and Rdea119 Label ), ALBUTEROL (2 Puffs/inhaler) (View Albuterol Review and Albuterol Label ), MUCINEX (200 Mg) (View Mucinex Review and Mucinex Label ), PROTONIX (Total Daily Dose: 80 Mg) (View Protonix Review and Protonix Label ), LOMOTIL (2.5 Mg) (View Lomotil Review and Lomotil Label ), FERROUS SULFATE (Total Daily Dose: 325 Mg) (View Ferrous Sulfate Review and Ferrous Sulfate Label ). Patient was hospitalized.

7009857-1 | Hepatic Function Abnormal
on Sep 14, 2010 Male patient from CHINA , 59 years of age, weighting 132.3 lb, was diagnosed with hepatic neoplasm malignant, hepatic function abnormal and was treated with Sorafenib (View Usage). Patient had the following side effects: hepatic function abnormal. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with BICYCLOL (View Bicyclol Review and Bicyclol Label ). Patient was hospitalized.

7009204-5 | Dermatitis, Rash, Vasculitis
on Sep 09, 2010 Male patient from RUSSIAN FEDERATION , 64 years of age, weighting 158.7 lb, was diagnosed with hepatic neoplasm malignant, hypertension and was treated with Sorafenib (View Usage). After Sorafenib was administered, patient had the following side effects: dermatitis, rash (What is rash?), vasculitis (What is vasculitis?). Sorafenib dosage: . During the same period patient was treated with ERLOTINIB HYDROCHLORIDE (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ), BETALOC (View Betaloc Review and Betaloc Label ), PREDUCTAL (View Preductal Review and Preductal Label ), MONOPRIL (View Monopril Review and Monopril Label ). Patient was hospitalized.

7009165-9 | Chest Pain, Dyspnoea, Haemoptysis, Non-small Cell Lung Cancer, Productive Cough
Patient was taking Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), dyspnoea, haemoptysis, non-small cell lung cancer, productive cough on Sep 21, 2010 from SINGAPORE Additional patient health information: Male patient , 62 years of age, was diagnosed with non-small cell lung cancer and. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with VINORELBINE (View Vinorelbine Review and Vinorelbine Label ). Patient was hospitalized.

7009126-X | Abdominal Hernia, Angiodysplasia, Hepatic Encephalopathy
Adverse event was reported on Sep 16, 2010 by a Male patient taking Sorafenib (View Usage) (Dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg) was diagnosed with hepatic neoplasm malignant and. Location: GERMANY , 62 years of age, weighting 205.0 lb, Patient had the following side effects: abdominal hernia, angiodysplasia, hepatic encephalopathy. Patient was hospitalized.

7009114-3 | Gastric Antral Vascular Ectasia
on Sep 17, 2010 Male patient from UNITED STATES , 67 years of age, was diagnosed with hepatic neoplasm malignant and was treated with Sorafenib (View Usage). After Sorafenib was administered, patient had the following side effects: gastric antral vascular ectasia. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. Patient was hospitalized.

7009113-1 | Hepatic Failure
on Sep 17, 2010 Female patient from UNITED STATES , 59 years of age, weighting 114.6 lb, was diagnosed with metastatic renal cell carcinoma and was treated with Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic failure. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. Patient was hospitalized.

7009043-5 | Dermatitis Psoriasiform, Rash Pustular, Skin Plaque
Patient was taking Sorafenib (View Usage). Patient had the following side effects: dermatitis psoriasiform, rash pustular, skin plaque on Aug 07, 2010 from UNITED STATES Additional patient health information: Male patient , 56 years of age, was diagnosed with hepatic neoplasm malignant and. Sorafenib dosage: .

7009035-6 | Diarrhoea, Palmar-plantar Erythrodysaesthesia Syndrome
Adverse event was reported on Jul 06, 2010 by a Female patient taking Sorafenib (View Usage) (Dosage: Total Daily Dose: 800 Mg) was diagnosed with adrenocortical carcinoma, hypertension and. Location: UNITED STATES , 56 years of age, weighting 185.2 lb, After Sorafenib was administered, patient had the following side effects: diarrhoea, palmar-plantar erythrodysaesthesia syndrome. During the same period patient was treated with FUROSEMIDE (View Furosemide Review and Furosemide Label ).

7007333-3 | Pleural Effusion
on Sep 17, 2010 Female patient from GERMANY , 64 years of age, was diagnosed with renal cell carcinoma and was treated with Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: pleural effusion. Sorafenib dosage: Total Daily Dose: 800 Mg. During the same period patient was treated with SUNITINIB MALATE (View Sunitinib Malate Review and Sunitinib Malate Label ), REDUCTO SPEZIAL (View Reducto Spezial Review and Reducto Spezial Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), MOBLOC (View Mobloc Review and Mobloc Label ), CIPRALEX (View Cipralex Review and Cipralex Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ). Patient was hospitalized.

7007321-7 | Diarrhoea, N-terminal Prohormone Brain Natriuretic Peptide, Urticaria
on Sep 17, 2010 Male patient from GERMANY , 62 years of age, was diagnosed with renal cell carcinoma and was treated with Sorafenib (View Usage). Patient had the following side effects: diarrhoea, n-terminal prohormone brain natriuretic peptide, urticaria. Sorafenib dosage: Total Daily Dose: 400 Mg. During the same period patient was treated with SUNITINIB MALATE (View Sunitinib Malate Review and Sunitinib Malate Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), BIOHEXAL (View Biohexal Review and Biohexal Label ), LOPERAMIDE (View Loperamide Review and Loperamide Label ).

7007245-5 | Disorientation, Encephalopathy
Patient was taking Sorafenib (View Usage). After Sorafenib was administered, patient had the following side effects: disorientation, encephalopathy on Sep 16, 2010 from RUSSIAN FEDERATION Additional patient health information: Male patient , 81 years of age, weighting 147.7 lb, was diagnosed with hepatic neoplasm malignant, hypertension and. Sorafenib dosage: . During the same period patient was treated with NIFEDIPINE (View Nifedipine Review and Nifedipine Label ). Patient was hospitalized and became disabled.

7007223-6 | Acute Hepatic Failure
Adverse event was reported on Sep 10, 2010 by a Female patient taking Sorafenib (View Usage) (Dosage: As Used: 800 Mg Unit Dose: 200 Mg) was diagnosed with hepatic neoplasm malignant and. Location: SPAIN , 68 years of age, weighting 116.8 lb, Patient experienced the following unwanted or unexpected effects: acute hepatic failure. During the same period patient was treated with FUROSEMIDE (As Used: 40 Mg) (View Furosemide Review and Furosemide Label ), SPIRONOLACTONE (As Used: 100 Mg) (View Spironolactone Review and Spironolactone Label ), VITAMINA K (1 Amp/day) (View Vitamina K Review and Vitamina K Label ), OMEPRAZOLE (As Used: 20 Mg) (View Omeprazole Review and Omeprazole Label ), NUTRICOMP HEPA (500 Ml/day) (View Nutricomp Hepa Review and Nutricomp Hepa Label ).

7007200-5 | Fall, Pancreatic Carcinoma, Pyothorax, Subarachnoid Haemorrhage, Thrombocytopenia
on Sep 15, 2010 Female patient from UNITED STATES , 54 years of age, weighting 125.7 lb, was diagnosed with pancreatic carcinoma and was treated with Sorafenib (View Usage). Patient had the following side effects: fall (What is fall?), pancreatic carcinoma, pyothorax, subarachnoid haemorrhage, thrombocytopenia. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with RDEA119 (Total Daily Dose: 100 Mg) (View Rdea119 Review and Rdea119 Label ). Patient was hospitalized.

7004675-2 | Anaemia, Leukopenia, Pancytopenia, Thrombocytopenia
on Jul 14, 2010 Male patient from GERMANY , 74 years of age, weighting 183.0 lb, was diagnosed with acute myeloid leukaemia and was treated with Sorafenib (View Usage). After Sorafenib was administered, patient had the following side effects: anaemia, leukopenia, pancytopenia, thrombocytopenia. Sorafenib dosage: . During the same period patient was treated with DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ARA C (View Ara-c Review and Ara-c Label ). Patient was hospitalized.

7001745-X | Ascites, Dyspnoea, Lethargy
Patient was taking Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: ascites, dyspnoea, lethargy on Sep 06, 2010 from SINGAPORE Additional patient health information: Male patient , 61 years of age, weighting 127.9 lb, was diagnosed with hepatic neoplasm malignant, abdominal discomfort, blood albumin decreased, hepatitis (What is hepatitis?), hepatic vein thrombosis and. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with PARACETAMOL (View Paracetamol Review and Paracetamol Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), 20% ALBUMIN (View 20% Albumin Review and 20% Albumin Label ), LAMIVUDINE (View Lamivudine Review and Lamivudine Label ), CLEXANE (View Clexane Review and Clexane Label ). Patient was hospitalized.

7001744-8 | Cardiac Disorder, Neoplasm
Adverse event was reported on Sep 06, 2010 by a Female patient taking Sorafenib (View Usage) (Dosage: Total Daily Dose: 400 Mg Unit Dose: 200 Mg) was diagnosed with neoplasm, hypertension, prophylaxis, cardiovascular event prophylaxis and. Location: POLAND , 64 years of age, weighting 220.5 lb, Patient had the following side effects: cardiac disorder, neoplasm. During the same period patient was treated with BISOCARD (View Bisocard Review and Bisocard Label ), AMLOPI (View Amlopi Review and Amlopi Label ), PIRAMIL (View Piramil Review and Piramil Label ), THEOVENT (View Theovent Review and Theovent Label ), ACARD (View Acard Review and Acard Label ). Patient was hospitalized.

7001727-8 | Chest Pain, Dyspnoea, Haemoptysis, Non-small Cell Lung Cancer, Productive Cough
on Sep 06, 2010 Male patient from SINGAPORE , 62 years of age, was diagnosed with non-small cell lung cancer and was treated with Sorafenib (View Usage). After Sorafenib was administered, patient had the following side effects: chest pain (What is chest pain?), dyspnoea, haemoptysis, non-small cell lung cancer, productive cough. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with VINORELBINE (View Vinorelbine Review and Vinorelbine Label ). Patient was hospitalized.

6998580-5 | Chest Discomfort, Dyspnoea, Electrolyte Imbalance, Nausea, Restlessness
on Sep 14, 2010 Female patient from CHINA , 32 years of age, weighting 121.3 lb, was diagnosed with nasopharyngeal cancer and was treated with Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: chest discomfort, dyspnoea, electrolyte imbalance, nausea (What is nausea?), restlessness. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ).

6988508-6 | Acute Graft Versus Host Disease, Diarrhoea, Ileal Perforation, Ileus, Leukopenia, Mucormycosis, Peritoneal Infection, Rash, Small Intestinal Stenosis
Patient was taking Sorafenib (View Usage). Patient had the following side effects: acute graft versus host disease, diarrhoea, ileal perforation, ileus, leukopenia, mucormycosis, peritoneal infection, rash (What is rash?), small intestinal stenosis on Sep 08, 2010 from GERMANY Additional patient health information: Female patient , 21 years of age, was diagnosed with acute myeloid leukaemia, stem cell transplant, immunosuppression and. Sorafenib dosage: . During the same period patient was treated with FLUDARABINE (View Fludarabine Review and Fludarabine Label ), PREDNISOLONE (High Dose; Could Be Reduced To 10 Mg/day) (View Prednisolone Review and Prednisolone Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), ARAC (View Arac Review and Arac Label ).

6987266-9 | Cardio-respiratory Arrest
Adverse event was reported on Sep 10, 2010 by a Male patient taking Sorafenib (View Usage) (Dosage: Total Daily Dose: 800 Mg) was diagnosed with renal cell carcinoma and. Location: UNITED STATES , 66 years of age, weighting 253.5 lb, After Sorafenib was administered, patient had the following side effects: cardio-respiratory arrest.

6987263-3 | Febrile Neutropenia, Myositis
on Sep 10, 2010 Male patient from UNITED STATES , 65 years of age, weighting 154.3 lb, was diagnosed with myelodysplastic syndrome and was treated with Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, myositis (What is myositis?). Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with PRILOSEC OTC (Total Daily Dose: 1 Df) (View Prilosec Otc Review and Prilosec Otc Label ), ALLEGRA D 24 HOUR (Total Daily Dose: 1 Df) (View Allegra D 24 Hour Review and Allegra D 24 Hour Label ). Patient was hospitalized.

6987259-1 | Diarrhoea, N-terminal Prohormone Brain Natriuretic Peptide, Urticaria
on Sep 14, 2010 Male patient from GERMANY , 62 years of age, was diagnosed with renal cell carcinoma and was treated with Sorafenib (View Usage). Patient had the following side effects: diarrhoea, n-terminal prohormone brain natriuretic peptide, urticaria. Sorafenib dosage: Total Daily Dose: 400 Mg. During the same period patient was treated with SUNITINIB MALATE (View Sunitinib Malate Review and Sunitinib Malate Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), BIOHEXAL (View Biohexal Review and Biohexal Label ), LOPERAMIDE (View Loperamide Review and Loperamide Label ).

6987198-6 | Dermatitis, Rash, Vasculitis
Patient was taking Sorafenib (View Usage). After Sorafenib was administered, patient had the following side effects: dermatitis, rash (What is rash?), vasculitis (What is vasculitis?) on Sep 09, 2010 from RUSSIAN FEDERATION Additional patient health information: Male patient , 64 years of age, weighting 158.7 lb, was diagnosed with hepatic neoplasm malignant, hypertension and. Sorafenib dosage: . During the same period patient was treated with BETALOC (View Betaloc Review and Betaloc Label ), PREDUCTAL (View Preductal Review and Preductal Label ), MONOPRIL (View Monopril Review and Monopril Label ). Patient was hospitalized.

6984762-5 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Bilirubin Increased
Adverse event was reported on Sep 09, 2010 by a Male patient taking Sorafenib (View Usage) (Dosage: Total Daily Dose: 800 Mg) was diagnosed with hepatic neoplasm malignant, hepatic function abnormal, gastric ph decreased, infection prophylaxis and. Location: UNITED STATES , 53 years of age, weighting 143.3 lb, Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased. During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), GLYCYRRHIZIN (8 Vials) (View Glycyrrhizin Review and Glycyrrhizin Label ), TIOPRONIN (View Tiopronin Review and Tiopronin Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), FLOXACILLIN SODIUM (View Floxacillin Sodium Review and Floxacillin Sodium Label ). Patient was hospitalized.

6984713-3 | Fall, Pyothorax, Subarachnoid Haemorrhage, Thrombocytopenia
on Sep 11, 2010 Female patient from UNITED STATES , 54 years of age, weighting 143.3 lb, was diagnosed with pancreatic carcinoma and was treated with Sorafenib (View Usage). Patient had the following side effects: fall (What is fall?), pyothorax, subarachnoid haemorrhage, thrombocytopenia. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with RDEA119 (Total Daily Dose: 100 Mg) (View Rdea119 Review and Rdea119 Label ). Patient was hospitalized.

6984708-X | Eye Oedema, Herpes Zoster Ophthalmic
on Sep 10, 2010 Male patient from UNITED STATES , 76 years of age, weighting 165.3 lb, was diagnosed with hepatic neoplasm malignant, hypertension, proctalgia, gastrooesophageal reflux disease, diarrhoea and was treated with Sorafenib (View Usage). After Sorafenib was administered, patient had the following side effects: eye oedema, herpes zoster ophthalmic. Sorafenib dosage: Total Daily Dose: 800 Mg. During the same period patient was treated with NITRENDIPINE (Total Daily Dose: 80 Mg) (View Nitrendipine Review and Nitrendipine Label ), FENOFIBRATE (Total Daily Dose: 640 Mg) (View Fenofibrate Review and Fenofibrate Label ), ALOPLASTINE (1 Application As Needed) (View Aloplastine Review and Aloplastine Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), LOPERAMIDE (Total Daily Dose: 60 Mg) (View Loperamide Review and Loperamide Label ).

6980364-5 | Hypoglycaemia
Patient was taking Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: hypoglycaemia on Sep 03, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 72 years of age, weighting 143.3 lb, was diagnosed with hepatic neoplasm malignant and. Sorafenib dosage: Total Daily Dose: 800 Mg. Patient was hospitalized.

6980357-8 | Atrial Fibrillation, Blood Alkaline Phosphatase Increased, Hyponatraemia, Nausea, Pain, Renal Cell Carcinoma
Adverse event was reported on Sep 08, 2010 by a Female patient taking Sorafenib (View Usage) (Dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg) was diagnosed with renal cell carcinoma, depression (What is depression?), prophylaxis, pain (What is pain?), nausea (What is nausea?), vitamin supplementation and. Location: UNITED STATES , 62 years of age, Patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), blood alkaline phosphatase increased, hyponatraemia, nausea (What is nausea?), pain (What is pain?), renal cell carcinoma. During the same period patient was treated with CIPRALEX (View Cipralex Review and Cipralex Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), IRBESARTAN (View Irbesartan Review and Irbesartan Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ), PINEX (View Pinex Review and Pinex Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ), EMPERAL (View Emperal Review and Emperal Label ), UNIKALK (View Unikalk Review and Unikalk Label ). Patient was hospitalized.

6980355-4 | Gastric Antral Vascular Ectasia
on Sep 07, 2010 Male patient from UNITED STATES , 67 years of age, was diagnosed with hepatic neoplasm malignant and was treated with Sorafenib (View Usage). After Sorafenib was administered, patient had the following side effects: gastric antral vascular ectasia. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. Patient was hospitalized.

6980353-0 | Anaemia, Diarrhoea, Dyspnoea, Fatigue, Hypokalaemia
on Sep 03, 2010 Female patient from UNITED STATES , 65 years of age, weighting 141.1 lb, was diagnosed with colorectal cancer metastatic, pulmonary congestion, diarrhoea, mineral supplementation and was treated with Sorafenib (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, diarrhoea, dyspnoea, fatigue, hypokalaemia. Sorafenib dosage: Total Daily Dose: 800 Mg Unit Dose: 200 Mg. During the same period patient was treated with RDEA119 (Total Daily Dose: 100 Mg) (View Rdea119 Review and Rdea119 Label ), ALBUTEROL (2 Puffs/inhaler) (View Albuterol Review and Albuterol Label ), MUCINEX (200 Mg) (View Mucinex Review and Mucinex Label ), PROTONIX (Total Daily Dose: 80 Mg) (View Protonix Review and Protonix Label ), LOMOTIL (2.5 Mg) (View Lomotil Review and Lomotil Label ), FERROUS SULFATE (Total Daily Dose: 325 Mg) (View Ferrous Sulfate Review and Ferrous Sulfate Label ). Patient was hospitalized.

6980288-3 | Hepatic Encephalopathy
Patient was taking Sorafenib (View Usage). Patient had the following side effects: hepatic encephalopathy on Aug 05, 2010 from HONG KONG Additional patient health information: Male patient , 74 years of age, weighting 191.8 lb, was diagnosed with hepatic neoplasm malignant, hypertension, hepatic cirrhosis, gastric ulcer, prophylaxis, blood pressure management and. Sorafenib dosage: . During the same period patient was treated with AMILORIDE HYDROCHLORIDE (View Amiloride Hydrochloride Review and Amiloride Hydrochloride Label ), ESSENTIALE (View Essentiale Review and Essentiale Label ), PEPCID (View Pepcid Review and Pepcid Label ), LACTULOSE (View Lactulose Review and Lactulose Label ), PROPRANOLOL (View Propranolol Review and Propranolol Label ).